Back to results
US 2026/0217704 A1Published application
Indolone derivative having irak4 inhibitory activity, and preparation method therefor and use thereof
AssigneeDovetree Medicines Unus, Inc.
InventorsXinMing DU, LiFei DU, ZhaoQiang CHEN, JunJun MA, ShaoHui WANG, Bin CHEN, PeiYu ZHANG
Life of this patent
Estimating the term…
Abstract
The present application relates to an indolone derivative having an IRAK4 inhibitory activity as represented by formula (I), a preparation method therefor and the use thereof, and further relates to a compound capable of inhibiting and degrading the IRAK4 protein and a pharmaceutical composition comprising the indolone derivative or the compound capable of inhibiting and degrading the IRAK4 protein.
Claims21
A compound of formula (I):
- or a stereoisomer, tautomer, diastereomer, racemate, cis/trans isomer, isotopically labeled compound (preferably deuterated compound), N-oxide, metabolite, ester, prodrug, crystal form, hydrate, solvate, or pharmaceutically acceptable salt thereof,
- wherein:
- ring {circle around (A)} is selected from:
- C3-10 cyclohydrocarbyl, 5- to 10-membered heterocyclyl, C6-10 aryl, and 5- to 10-membered heteroaryl;
- X1, X2, X3, and X4 are each independently N or CH;
- and at least one of X1, X2, X3, and X4 is not N;
- Y is O or S;
- Z is N or CR4;
- the characters “a” and “b” respectively indicate bonds between a ring carbon atom connected to Z and two adjacent ring carbon atoms;
- wherein:
- when Z is CR4, the moiety
- is represented by the following structure of formula (i) or (ii):
- when Z is N, the moiety
- is represented by the following structure of formula (iii) or (iv):
- L1 is selected from:
- a direct bond, O, S, C(O), S(O), S(O)2, and NR7;
- R1 is -L2-R1a;
- L2 is —NR1b—*, —S(O)2NR1b—*, —C(O)—NR1b—*, —CR1cR1d—NR1b—*, —NR1b—C(O)—*, or —NR1b—S(O)2—*, wherein the bond indicated by * is connected to R1a;
- R1a is selected from:
- C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 haloalkenyl, —C1-6 alkylene-O—C1-6 alkyl, —OC1-6 alkylene-OC1-6 alkyl, —C1-6 alkylene-OH, —C1-6 alkylene-SH, —C1-6 alkylene-CN, —C1-6 alkylene-NR1eR1f, and cyclic group Cy1, wherein the cyclic group Cy1 is selected from C3-10 cyclohydrocarbyl, 3- to 10-membered heterocyclyl, C6-10 aryl, and 5- to 10-membered heteroaryl, wherein the C3-10 cyclohydrocarbyl, 3- to 10-membered heterocyclyl, C6-10 aryl, and 5- to 10-membered heteroaryl are each optionally substituted with one or more substituents independently selected from the following groups:
- halogen, OH, SH, —NR1eR1f CN, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 haloalkenyl, —O—C1-6 alkyl, —O—C1-6 haloalkyl, —S—C1-6 alkyl, —C1-6 alkylene-O—C1-6 alkyl, —OC1-6 alkylene-OC1-6 alkyl, —C1-6 alkylene-OH, —C1-6 alkylene-SH, —C1-6 alkylene-CN, and —C1-6 alkylene-NR1eR1f;
- R1c and R1d and each R2 are independently selected from:
- H, halogen, OH, SH, —NR2aR2b, CN, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 haloalkenyl, —O—C1-6 alkyl, —O—C1-6 haloalkyl, —S—C1-6 alkyl, —C1-6 alkylene-O—C1-6 alkyl, —OC1-6 alkylene-OC1-6 alkyl, —C1-6 alkylene-OH, —C1-6 alkylene-SH, —C1-6 alkylene-CN, and —C1-6 alkylene-NR2aR2b;
- m is 0, 1, 2, or 3;
- R3 and R7 are each independently selected from:
- H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 haloalkenyl, —C1-6 alkylene-O—C1-6 alkyl, —C1-6 alkylene-OH, —C1-6 alkylene-SH, —C1-6 alkylene-CN, and —C1-6 alkylene-NR3aR3b;
- R4 is selected from:
- H, D, halogen, OH, SH, —NR4aR4b, CN, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 haloalkenyl, —C1-6 alkylene-O—C1-6 alkyl, —C1-6 alkylene-OH, —C1-6 alkylene-SH, —C1-6 alkylene-CN, and —C1-6 alkylene-NR4aR4b;
- R5 is selected from:
- halogen, OH, SH, —NR5aR5b, CN, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 haloalkenyl, —O—C1-6 alkyl, —O—C1-6 haloalkyl, —S—C1-6 alkyl, —C1-6 alkylene-O—C1-6 alkyl, —OC1-6 alkylene-OC1-6 alkyl, —C1-6 alkylene-OH, —C1-6 alkylene-SH, —C1-6 alkylene-CN, —C1-6 alkylene-NR5aR5b, cyclic group Cy2, and —C1-6 alkylene-Cy2, wherein the group Cy2 is selected from C3-10 cyclohydrocarbyl, 3- to 10-membered heterocyclyl, C6-10 aryl, and 5- to 10-membered heteroaryl, wherein the C3-10 cyclohydrocarbyl, 3- to 10-membered heterocyclyl, C6-10 aryl, and 5- to 10-membered heteroaryl are each optionally substituted with one or more substituents independently selected from the following groups:
- halogen, OH, SH, —NR5aR5b, CN, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 haloalkenyl, —O—C1-6 alkyl, —O—C1-6 haloalkyl, —S—C1-6 alkyl, —C1-6 alkylene-O—C1-6 alkyl, —OC1-6 alkylene-OC1-6 alkyl, —C1-6 alkylene-OH, —C1-6 alkylene-SH, —C1-6 alkylene-CN, and —C1-6 alkylene-NR5aR5b;
- R6 is selected from:
- halogen, OH, SH, —NR6aR6b, CN, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 haloalkenyl, —O—C1-6 alkyl, —O—C1-6 haloalkyl, —S—C1-6 alkyl, —C1-6 alkylene-O—C1-6 alkyl, —OC1-6 alkylene-OC1-6 alkyl, —C1-6 alkylene-OH, —C1-6 alkylene-SH, —C1-6 alkylene-CN, and —C1-6 alkylene-NR6aR6b;
- n is 0, 1, 2, 3, or 4;
- and
- R1b, R1e, R1f, R2a, R2b, R3a, R3b, R4a, R4b, R5a, R5b, R6a, and R6b are, at each occurrence, independently selected from H and C1-6 alkyl.
33 more elements
(canceled)
(canceled)
Dependencies are inferred from the claim text.